Simvastatin has been shown to suppress hypoxia‐inducible factor‐1α/PPARγ/pyruvate kinase type M2‐mediated glycolysis to re‐sensitize HCC cells to sorafenib.110. This evidence concerns the gene PPARG and hepatocellular carcinoma.